ADMA BIOLOGICS, INC. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. ADMA Biologics, Inc. is a U.S.-based biopharmaceutical company focused on manufacturing and marketing specialty biologics, primarily immune globulins (IVIG) for immunodeficient patients. The company operates two main segments: ADMA BioManufacturing (manufacturing and commercialization of ASCENIV, BIVIGAM, and Nabi-HB) and ADMA BioCenters (source plasma collection). As of August 1, 2025, there were approximately 238.6 million shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenues | $121.98 million | $107.19 million | $236.79 million | $189.07 million |
| Gross Profit | $67.23 million | $57.45 million | $128.32 million | $96.56 million |
| Gross Margin | 55.1% | 53.6% | 54.2% | 51.1% |
| Net Income | $34.22 million | $32.06 million | $61.12 million | $49.87 million |
| Diluted EPS | $0.14 | $0.13 | $0.25 | $0.21 |
| Cash from Operations | N/A | N/A | $1.46 million | $43.43 million |
| Cash & Equivalents (End of Period) | $90.29 million | N/A | $90.29 million | N/A |
| Total Debt (Senior Notes) | $73.40 million | N/A | $73.40 million | N/A |
Note: Q2 2025 cash flow from operations is not explicitly broken out in the provided text, but the six-month figure is $1.46 million.
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 14% in Q2 2025 and 25% YTD 2025 compared to the prior year periods. This growth is primarily driven by increased sales volume of ASCENIV due to higher physician, payer, and patient acceptance.
- Margin Expansion: Gross margins improved to 55.1% in Q2 2025 (from 53.6% in Q2 2024) and 54.2% YTD (from 51.1% YTD 2024). This is attributed to a more favorable product mix (higher margin IG sales) and operational efficiencies.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses increased significantly ($22.2M in Q2 2025 vs. $16.6M in Q2 2024) due to higher compensation costs, increased headcount, and stock-based compensation.
- Debt Restructuring: In May 2025, the company repaid $30.0 million of its term loan using proceeds from its revolving credit facility, resulting in a $1.16 million loss on extinguishment of debt.
- Voluntary Withdrawal: The company voluntarily withdrew three lots of BIVIGAM as a precautionary measure, resulting in a revenue reduction of $0.2 million in Q2 2025 and $4.0 million YTD 2025.
Guidance, Outlook, and Risks
- Yield Enhancement: In April 2025, the FDA approved a Prior Approval Supplement (PAS) for an innovative yield enhancement production process. This is expected to increase ASCENIV and BIVIGAM production yields by approximately 20% from the same raw material volume, with meaningful revenue and earnings accretion expected beginning in the second half of 2025.
- Pediatric Expansion: The company filed a supplemental Biologics License Application (sBLA) in June 2025 to expand ASCENIV's label to include pediatric patients (two years and older), anticipating potential FDA approval in the first half of 2026.
- Capital Expenditures: The company expects total capital expenditures for the remainder of fiscal 2025 to be between $18.0 million and $21.6 million, including a $12.6 million real estate acquisition in Boca Raton, FL (completed in July 2025) to expand production and storage.
- Debt Refinancing (Subsequent Event): On August 5, 2025, the company entered into a new $300 million credit facility with JPMorgan Chase Bank, N.A., replacing the previous Ares facility. This includes a $75 million term loan and a $225 million revolving facility, maturing in August 2028.
- Share Repurchases: In May 2025, the Board authorized a $500 million share repurchase program. During Q2 2025, the company repurchased 816,237 shares for approximately $15.1 million.
- Risks: Key risks include reliance on third-party suppliers for plasma and fill-finish services, regulatory compliance (FDA inspections), potential supply constraints for high-titer RSV plasma, and the impact of inflation on raw material costs.
Investor Verification Checklist
- Debt Refinancing Terms: Verify the specific interest rate margins and covenants of the new JPMorgan credit facility closed in August 2025.
- Yield Enhancement Realization: Monitor Q3 and Q4 2025 results to confirm the anticipated 20% yield increase and its impact on gross margins.
- ASCENIV Pediatric Approval: Track the status of the sBLA filed in June 2025 for the pediatric indication.
- Customer Concentration: Note that three customers accounted for approximately 90% of accounts receivable as of June 30, 2025.
- Cash Flow Volatility: Review the significant decrease in operating cash flow YTD 2025 ($1.5M) compared to YTD 2024 ($43.4M), driven by inventory build-up and timing of sales.